Fig 1.

Progression-free survival (PFS) analysis (intent-to-treat population). For analyses of PFS, patients who started another antimyeloma therapy before documented disease progression or patients with missing assessments are censored. (A) Kaplan-Meier estimates of PFS. (B) Hazard ratios (HRs) for PFS by individual study. (C) HRs for PFS by subgroup. (*) The size of each blue box corresponds to the size of the individual study. The CI is a function of the overall sample size. (†) Age at random assignment was available and used for the Cancer and Leukemia Group B (CALGB) 100104 study¹⁹ and the Intergroupe Francophone du Myélome (IFM) 2005-02 study²⁰. Only age at diagnosis was available for the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) RV-MM-PI-209 study². (‡) The International Staging System (ISS) stage was based on β₂-microglobulin and albumin at diagnosis for the GIMEMA and IFM studies and at registration for the CALGB study. (§) Upon central review, four patients did not meet the criteria for stable disease (SD). ASCT, autologous stem-cell transplantation; CR, complete response; Len, lenalidomide; PR, partial response; VGPR, very good partial response.